Restructure
Purdue Pharma Bankruptcy
In November 2025, the United States Bankruptcy Court for the Southern District of New York approved the Chapter 11 Plan of Reorganization for Purdue Pharma L.P. Read the press release here.
The Plan, which achieved remarkable consensus with the support of more than 99% of voting creditors, will deliver billions in urgently needed funding for opioid crisis abatement and victim compensation, as well as rescue medicines that will save lives.
The terms of the Plan and disclosure statement as filed can be viewed here. Any questions can be directed to the restructuring information line at +1 (844) 217-0912 or, if you are calling from outside the U.S. or Canada, +1 (347-859-8093). Case documents may also be found at https://restructuring.ra.kroll.com/purduepharma/Home-DocketInfo.
With confirmation of the Plan secured, Purdue is working on the steps necessary for consummation. The Plan and its related settlements will deliver the abatement initiative funding and victim compensation that have been the company’s goal throughout the bankruptcy process. Those funds will flow once we reach the effective date.
The business continues uninterrupted. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners and customers. The Company will continue serving those who rely on its medicines, pursuing its pipeline, and introducing medicines that will help save and improve lives.